Diagnosis and management of the neuroinflammatory diseases of the central nervous system (CNS) are hindered by the lack of reliable biomarkers of active intrathecal inflammation. We hypothesized that measuring several putative inflammatory biomarkers simultaneously will augment specificity and sensitivity of the biomarker to the clinically useful range. Based on our pilot experiment in which we measured 18 inflammatory biomarkers in 10-fold concentrated cerebrospinal fluid (CSF) derived from 16 untreated patients with highly active multiple sclerosis (MS) we selected a combination of three CSF biomarkers, IL-12p40, CXCL13 and IL-8, for further validation. Concentrations of IL-12p40, CXCL13 and IL-8 were determined in a blinded fashion in CSF samples from an initial cohort (n = 72) and a confirmatory cohort (n = 167) of prospectively collected, untreated subjects presenting for a diagnostic work-up of possible neuroimmunological disorder. Diagnostic conclusion was based on a thorough clinical workup, which included laboratory assessment of the blood and CSF, neuroimaging and longitudinal follow-up. Receiver operating characteristic (ROC) curve analysis in conjunction with principal component analysis (PCA), which was used to combine information from all three biomarkers, assessed the diagnostic value of measured biomarkers. Each of the three biomarkers was significantly increased in MS and other inflammatory neurological disease (OIND) in comparison to non-inflammatory neurological disorder patients (NIND) at least in one cohort. However, considering all three biomarkers together improved accuracy of predicting the presence of intrathecal inflammation to the consistently good to excellent range (area under the ROC curve = 0.868–0.924). Future clinical studies will determine if a combinatorial biomarker consisting of CSF IL-12p40, CXCL13 and IL-8 provides utility in determining the presence of active intrathecal inflammation in diagnostically uncertain cases and in therapeutic development and management.
References
[1]
Frischer JM, Bramow S, Dal-Bianco A, Lucchinetti CF, Rauschka H, et al. (2009) The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain
[2]
Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, et al. (2007) Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 130: 1089–1104.
[3]
Androdias G, Reynolds R, Chanal M, Ritleng C, Confavreux C, et al. (2010) Meningeal T cells associate with diffuse axonal loss in multiple sclerosis spinal cords. Ann Neurol 68: 465–476.
[4]
Cross AH, Stark JL, Lauber J, Ramsbottom MJ, Lyons JA (2006) Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 180: 63–70.
[5]
Rudick RA, Cookfair DL, Simonian NA, Ransohoff RM, Richert JR, et al. (1999) Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. J Neuroimmunol 93: 8–14.
[6]
Bielekova B, Richert N, Herman ML, Ohayon J, Waldmann TA, et al. (2011) Intrathecal effects of daclizumab treatment of multiple sclerosis. Neurology 77: 1877–1886.
[7]
Kanangat S, Thomas J, Gangappa S, Babu JS, Rouse BT (1996) Herpes simplex virus type 1-mediated up-regulation of IL-12 (p40) mRNA expression. Implications in immunopathogenesis and protection. J Immunol 156: 1110–1116.
[8]
Kichian K, Nestel FP, Kim D, Ponka P, Lapp WS (1996) IL-12 p40 messenger RNA expression in target organs during acute graft-versus-host disease. Possible involvement of IFN-gamma. J Immunol 157: 2851–2856.
[9]
Cooper AM, Khader SA (2007) IL-12p40: an inherently agonistic cytokine. Trends Immunol 28: 33–38.
[10]
Dobreva ZG, Stanilova SA, Miteva LD (2008) Differences in the inducible gene expression and protein production of IL-12p40, IL-12p70 and IL-23: involvement of p38 and JNK kinase pathways. Cytokine 43: 76–82.
[11]
Ling P, Gately MK, Gubler U, Stern AS, Lin P, et al. (1995) Human IL-12 p40 homodimer binds to the IL-12 receptor but does not mediate biologic activity. J Immunol 154: 116–127.
[12]
Holscher C (2004) The power of combinatorial immunology: IL-12 and IL-12-related dimeric cytokines in infectious diseases. Med Microbiol Immunol 193: 1–17.
[13]
Germann T, Rude E, Mattner F, Gately MK (1995) The IL-12 p40 homodimer as a specific antagonist of the IL-12 heterodimer. Immunol Today 16: 500–501.
[14]
Yoshimoto T, Wang CR, Yoneto T, Waki S, Sunaga S, et al. (1998) Reduced T helper 1 responses in IL-12 p40 transgenic mice. J Immunol 160: 588–594.
[15]
Shimozato O, Ugai S, Chiyo M, Takenobu H, Nagakawa H, et al. (2006) The secreted form of the p40 subunit of interleukin (IL)-12 inhibits IL-23 functions and abrogates IL-23-mediated antitumour effects. Immunology 117: 22–28.
[16]
Abdi K (2002) IL-12: the role of p40 versus p75. Scand J Immunol 56: 1–11.
[17]
Klinke DJ 2nd (2006) The ratio of P40 monomer to dimer is an important determinant of IL-12 bioactivity. J Theor Biol 240: 323–335.
[18]
Slight SR, Lin Y, Messmer M, Khader SA (2011) Francisella tularensis LVS-induced Interleukin-12 p40 cytokine production mediates dendritic cell migration through IL-12 Receptor beta1. Cytokine 55: 372–379.
[19]
Russell TD, Yan Q, Fan G, Khalifah AP, Bishop DK, et al. (2003) IL-12 p40 homodimer-dependent macrophage chemotaxis and respiratory viral inflammation are mediated through IL-12 receptor beta 1. J Immunol 171: 6866–6874.
[20]
Jana M, Dasgupta S, Pal U, Pahan K (2009) IL-12 p40 homodimer, the so-called biologically inactive molecule, induces nitric oxide synthase in microglia via IL-12R beta 1. Glia 57: 1553–1565.
[21]
Jana M, Pahan K (2009) Induction of lymphotoxin-alpha by interleukin-12 p40 homodimer, the so-called biologically inactive molecule, but not IL-12 p70. Immunology 127: 312–325.
[22]
Piccotti JR, Chan SY, Li K, Eichwald EJ, Bishop DK (1997) Differential effects of IL-12 receptor blockade with IL-12 p40 homodimer on the induction of CD4+ and CD8+ IFN-gamma-producing cells. J Immunol 158: 643–648.
[23]
Windhagen A, Newcombe J, Dangond F, Strand C, Woodroofe MN, et al. (1995) Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. J Exp Med 182: 1985–1996.
[24]
Sellebjerg F, Bornsen L, Khademi M, Krakauer M, Olsson T, et al. (2009) Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology 73: 2003–2010.
[25]
Khademi M, Kockum I, Andersson ML, Iacobaeus E, Brundin L, et al. (2010) Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. Mult Scler
[26]
Krumbholz M, Theil D, Cepok S, Hemmer B, Kivisakk P, et al. (2006) Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain 129: 200–211.
[27]
Ragheb S, Li Y, Simon K, VanHaerents S, Galimberti D, et al. (2011) Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid. Mult Scler 17: 819–829.
[28]
Brettschneider J, Czerwoniak A, Senel M, Fang L, Kassubek J, et al. (2010) The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS). PLoS One 5: e11986.
[29]
Marra CM, Tantalo LC, Sahi SK, Maxwell CL, Lukehart SA (2010) CXCL13 as a cerebrospinal fluid marker for neurosyphilis in HIV-infected patients with syphilis. Sex Transm Dis 37: 283–287.
[30]
van Burgel ND, Bakels F, Kroes AC, van Dam AP (2011) Discriminating Lyme neuroborreliosis from other neuroinflammatory diseases by levels of CXCL13 in cerebrospinal fluid. J Clin Microbiol 49: 2027–2030.
[31]
Zhong X, Wang H, Dai Y, Wu A, Bao J, et al. (2011) Cerebrospinal fluid levels of CXCL13 are elevated in neuromyelitis optica. J Neuroimmunol 240–241: 104–108.
[32]
Pranzatelli MR, Tate ED, McGee NR, Travelstead AL, Ransohoff RM, et al. (2012) Key role of CXCL13/CXCR5 axis for cerebrospinal fluid B cell recruitment in pediatric OMS. J Neuroimmunol 243: 81–88.
[33]
Vissers JL, Hartgers FC, Lindhout E, Figdor CG, Adema GJ (2001) BLC (CXCL13) is expressed by different dendritic cell subsets in vitro and in vivo. Eur J Immunol 31: 1544–1549.
[34]
Carlsen HS, Baekkevold ES, Morton HC, Haraldsen G, Brandtzaeg P (2004) Monocyte-like and mature macrophages produce CXCL13 (B cell-attracting chemokine 1) in inflammatory lesions with lymphoid neogenesis. Blood 104: 3021–3027.
[35]
Smith JR, Braziel RM, Paoletti S, Lipp M, Uguccioni M, et al. (2003) Expression of B-cell-attracting chemokine 1 (CXCL13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma. Blood 101: 815–821.
[36]
Falkenhagen KM, Braziel RM, Fraunfelder FW, Smith JR (2005) B-Cells in ocular adnexal lymphoproliferative lesions express B-cell attracting chemokine 1 (CXCL13). Am J Ophthalmol 140: 335–337.
[37]
Ortonne N, Dupuis J, Plonquet A, Martin N, Copie-Bergman C, et al. (2007) Characterization of CXCL13+ neoplastic t cells in cutaneous lesions of angioimmunoblastic T-cell lymphoma (AITL). Am J Surg Pathol 31: 1068–1076.
[38]
Manzo A, Paoletti S, Carulli M, Blades MC, Barone F, et al. (2005) Systematic microanatomical analysis of CXCL13 and CCL21 in situ production and progressive lymphoid organization in rheumatoid synovitis. Eur J Immunol 35: 1347–1359.
[39]
Salomonsson S, Larsson P, Tengner P, Mellquist E, Hjelmstrom P, et al. (2002) Expression of the B cell-attracting chemokine CXCL13 in the target organ and autoantibody production in ectopic lymphoid tissue in the chronic inflammatory disease Sjogren's syndrome. Scand J Immunol 55: 336–342.
[40]
Amft N, Curnow SJ, Scheel-Toellner D, Devadas A, Oates J, et al. (2001) Ectopic expression of the B cell-attracting chemokine BCA-1 (CXCL13) on endothelial cells and within lymphoid follicles contributes to the establishment of germinal center-like structures in Sjogren's syndrome. Arthritis Rheum 44: 2633–2641.
[41]
Shi K, Hayashida K, Kaneko M, Hashimoto J, Tomita T, et al. (2001) Lymphoid chemokine B cell-attracting chemokine-1 (CXCL13) is expressed in germinal center of ectopic lymphoid follicles within the synovium of chronic arthritis patients. J Immunol 166: 650–655.
[42]
Meraouna A, Cizeron-Clairac G, Panse RL, Bismuth J, Truffault F, et al. (2006) The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis. Blood 108: 432–440.
[43]
Ohmatsu H, Sugaya M, Kadono T, Tamaki K (2007) CXCL13 and CCL21 are expressed in ectopic lymphoid follicles in cutaneous lymphoproliferative disorders. J Invest Dermatol 127: 2466–2468.
[44]
Rupprecht TA, Plate A, Adam M, Wick M, Kastenbauer S, et al. (2009) The chemokine CXCL13 is a key regulator of B cell recruitment to the cerebrospinal fluid in acute Lyme neuroborreliosis. J Neuroinflammation 6: 42.
[45]
Magliozzi R, Columba-Cabezas S, Serafini B, Aloisi F (2004) Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis. J Neuroimmunol 148: 11–23.
[46]
van de Pavert SA, Olivier BJ, Goverse G, Vondenhoff MF, Greuter M, et al. (2009) Chemokine CXCL13 is essential for lymph node initiation and is induced by retinoic acid and neuronal stimulation. Nat Immunol 10: 1193–1199.
[47]
Luther SA, Ansel KM, Cyster JG (2003) Overlapping roles of CXCL13, interleukin 7 receptor alpha, and CCR7 ligands in lymph node development. J Exp Med 197: 1191–1198.
[48]
Aloisi F, Care A, Borsellino G, Gallo P, Rosa S, et al. (1992) Production of hemolymphopoietic cytokines (IL-6, IL-8, colony-stimulating factors) by normal human astrocytes in response to IL-1 beta and tumor necrosis factor-alpha. J Immunol 149: 2358–2366.
[49]
Mellergard J, Edstrom M, Vrethem M, Ernerudh J, Dahle C (2010) Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid. Mult Scler 16: 208–217.
[50]
Ishizu T, Osoegawa M, Mei FJ, Kikuchi H, Tanaka M, et al. (2005) Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain 128: 988–1002.
[51]
Pinto Junior VL, Rebelo MC, Gomes RN, Assis EF, Castro-Faria-Neto HC, et al. (2011) IL-6 and IL-8 in cerebrospinal fluid from patients with aseptic meningitis and bacterial meningitis: their potential role as a marker for differential diagnosis. Braz J Infect Dis 15: 156–158.
[52]
Kleine TO, Zwerenz P, Graser C, Zofel P (2003) Approach to discriminate subgroups in multiple sclerosis with cerebrospinal fluid (CSF) basic inflammation indices and TNF-alpha, IL-1beta, IL-6, IL-8. Brain Res Bull 61: 327–346.
[53]
Sato S, Suzuki K, Nagao R, Kashiwagi Y, Kawashima H, et al. (2009) Detection of MCP-1 and IL-8 in the serum and cerebrospinal fluid of a child with Miller Fisher syndrome. J Clin Neurosci 16: 1698–1699.
[54]
Asano T, Ichiki K, Koizumi S, Kaizu K, Hatori T, et al. (2010) IL-8 in cerebrospinal fluid from children with acute encephalopathy is higher than in that from children with febrile seizure. Scand J Immunol 71: 447–451.
[55]
Katsumata Y, Harigai M, Kawaguchi Y, Fukasawa C, Soejima M, et al. (2007) Diagnostic reliability of cerebral spinal fluid tests for acute confusional state (delirium) in patients with systemic lupus erythematosus: interleukin 6 (IL-6), IL-8, interferon-alpha, IgG index, and Q-albumin. J Rheumatol 34: 2010–2017.
[56]
Kushi H, Saito T, Makino K, Hayashi N (2003) IL-8 is a key mediator of neuroinflammation in severe traumatic brain injuries. Acta Neurochir Suppl 86: 347–350.
[57]
McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, et al. (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50: 121–127.
[58]
Soreide K, Korner H, Soreide JA (2011) Diagnostic accuracy and receiver-operating characteristics curve analysis in surgical research and decision making. Ann Surg 253: 27–34.
[59]
Grund B, Sabin C (2010) Analysis of biomarker data: logs, odds ratios, and receiver operating characteristic curves. Curr Opin HIV AIDS 5: 473–479.
[60]
Zweig MH, Campbell G (1993) Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 39: 561–577.
[61]
Segal BM, Constantinescu CS, Raychaudhuri A, Kim L, Fidelus-Gort R, et al. (2008) Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol 7: 796–804.
[62]
Perry JS, Han S, Xu Q, Herman ML, Kennedy LB, et al. (2012) Inhibition of LTi Cell Development by CD25 Blockade Is Associated with Decreased Intrathecal Inflammation in Multiple Sclerosis. Sci Transl Med 4: 145ra106.
